HLB Co., Ltd.
028300
Rangering i aksjer
#4138
HLB Co., Ltd. operates in two distinct sectors: pharmaceutical production and... HLB Co., Ltd. operates in two distinct sectors: pharmaceutical production and naval construction. In South Korea, its maritime division produces and distributes a diverse range of lifeboats, catering to offshore platforms, drilling vessels, and passenger cruise liners. Its offerings include traditional, free-fall, and rescue boat designs. Beyond lifeboats, HLB's product portfolio extends to marine and yacht engines, hooks, and a variety of specialized vessels such as rigid inflatable (RIB), patrol, fishing, aluminum, and leisure boats, as well as fishery inspection ships and general safety equipment. The company further offers comprehensive support services, including inspection and repair of lifeboats and davits, service engineering training, and the provision of spare parts. On the pharmaceutical front, HLB is engaged in the development of Riboseranib, a targeted anti-cancer agent, and Apilia, a treatment specifically for ovarian cancer. Established in 1975, HLB Co., Ltd. is headquartered in Ulsan, South Korea.
Aksjekurs
$29.28
Markedsverdi
$3.89B
Endring (1 dag)
-1.40%
Endring (1 år)
-8.45%
Land
KR
Handel HLB Co., Ltd. (028300)
Kategori
Healthcare
Antall utestående aksjer for HLB Co., Ltd. (028300)
Antall utestående aksjer per June 2026: 132.90M
Ifølge HLB Co., Ltd. sine siste økonomiske rapporter og aksjekurs er antall utestående aksjer nå 132.90M. Ved slutten av December 2023 hadde selskapet 121.24M utestående aksjer. Antallet utestående aksjer påvirkes vanligvis av aksjesplitt og tilbakekjøp.
Historikk over utestående aksjer for HLB Co., Ltd. (028300) fra 2012 til 2026
Utestående aksjer ved utgangen av hvert år
| År | Utestående aksjer | Endre |
|---|---|---|
| 2026 (TTM) | 132.90M | 1.68% |
| 2024 | 130.70M | 7.81% |
| 2023 | 121.24M | 7.68% |
| 2022 | 112.59M | -6.32% |
| 2021 | 120.18M | -2.83% |
| 2020 | 123.68M | 22.11% |
| 2019 | 101.28M | 6.04% |
| 2018 | 95.51M | 4.49% |
| 2017 | 91.40M | 0.94% |
| 2016 | 90.55M | 7.76% |
| 2015 | 84.04M | 34.50% |
| 2014 | 62.48M | 7.44% |
| 2013 | 58.16M | 20.89% |
| 2012 | 48.11M | 0.00% |
Utestående aksjer for lignende selskaper eller konkurrenter
| Selskap | Utestående aksjer | Forskjell | Land |
|---|---|---|---|
| 253.90M | 91.04% |
US
|
|
| 396.00M | 197.96% |
US
|
|
| 478.91M | 260.35% |
AU
|
|
| 62.19M | -53.21% |
NL
|
|
| - | - |
CH
|
